My take on the rather surprising effect of apabetalone in the below median LDL subgroup is that it has to be seen in connection with the low eGFR subgroup. Thus, my current hypothesis is that Apabetalone (only?) works in patients with low eGFR and low LDL. The rationale for this is that low LDL is a risk factor in CKD patients. Non-CKD patients would normally benefit from an extremely low LDL, but CKD patients are actually at higher risk, not lower.

I would really like to see a plot of placebo vs. apabetalone in the low low LDL/low eGFR subgroup.

BR.

BKC